Dana-Farber Cancer Institute
44 Binney Street
287 articles with Dana-Farber Cancer Institute
Foundation Medicine and Dana-Farber Present Data at ASCO20 Showing that Comprehensive Genomic Profiling Identified Co-Occurring Alterations that May Cause Treatment Resistance in Patients with METex14-altered NSCLC
Alterations that cause skipping of exon 14 on the MET gene (METex14) are drivers of a type of lung cancer with a poor prognosis, but that is treatable with a recently approved MET inhibitor
Crown Bioscience Expands PDX Collection with Acquisition of Unique Models from Leading Academic Medical Centers
Agreements with CoMotion at the University of Washington and Dana-Farber Cancer Institute add new prostate cancer and lymphoma models to the world’s largest PDX collection
It will combine MPM’s venture capital investment fundraising with Dana-Farber’s philanthropic fundraising for cancer research.
2/17/2020It was a very busy week for clinical trial news. Here’s a look.
The study was in 55 patients who had an average of three previous treatment regimens. The results are promising enough that a Phase III trial is planned.
Vanderbilt Oncologists Publish Results of First Study to Demonstrate Clinical Utility of Resolution Liquid Biopsy Assay to Monitor Response and Resistance to Ensartinib
New Journal of Thoracic Oncology publication concludes prospective application of technology may translate to improved outcomes for non-small cell lung cancer patients
100 percent of dollars raised by Pan-Mass Challenge riders to further advancements in cancer research and treatment
A new blood test in development from GRAIL, Inc. and studied by investigators at the Dana-Farber Cancer Institute has the ability to accurately screen for numerous types of cancer.
Dana-Farber Cancer Institute unveiled a new visual identity, modernizing its logo and that of the Jimmy Fund with a vivid blue and gold palette.
Cancer cells appear to adapt to treatment with checkpoint blocker drugs by altering a metabolic process, leading to shorter survival for patients
Hyundai Hope On Wheels Presents Dana-Farber Cancer Institute with $500,000 Hyundai Young Investigator And Scholar Hope Grant To Support Pediatric Cancer Research
The Hyundai Hope On Wheels non-profit embarks on a nationwide tour this September during Childhood Cancer Awareness Month to award new grants for pediatric cancer, surpassing $160 million in lifetime funding for research. [20-September-2019] BOSTON , Sept. 20, 2019 /PRNewswire/ -- Hyundai Hope On Wheels® (HHOW), a 501(c)(3) non-profit organization supported by Hyu
Debbie's Dream Foundation to Host FREE Stomach Cancer Education Symposium and Live Webcast at Dana-Farber Cancer Institute
Patients, families, and caregivers are invited to learn about gastric cancer and other cancer-related issues from oncology experts
53 Valvoline Instant Oil Change locations in New England are participating in A Chance for Kids & Families® program for the 6th consecutive year to raise money for the Jimmy Fund
The decision, which is likely to be appealed, will allow Dana-Farber to license the technology.
U.S. District Court Rules Dana-Farber Scientist is an Inventor on Six Critical Immunotherapy Patents
The U. S. District Court ruled today that a Dana-Farber Cancer Institute scientist, Gordon Freeman, PhD, and another scientist, Clive Wood, PhD, are co-inventors on a series of cancer immunotherapy patents previously issued to a Japanese researcher and Japanese drug company, and ordered that the patents be corrected to name Freeman and Wood as inventors.
Resolution Liquid Biopsy Assay Outperforms Guardant360 in Retrospective Non-Small Cell Lung Carcinoma Comparison Pilot Study
Scientists from Dana-Farber Cancer Institute present results demonstrating detection of more actionable oncogenic fusions today at AACR Annual Meeting
Cancer Research UK, a cancer research and awareness charity in the United Kingdom and Isle of Man, recently announced its latest Grand Challenge winners. This cancer research grant awards a series of £20 million wards to international, multidisciplinary teams that focus on unique and new approach...
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
The Center for Protein Degradation will build upon the work of Dana-Farber researchers Nathanael Gray, PhD and Eric Fischer, PhD
Joseph Eid, head of medical at BMS, said Empliciti in combination with pomalidomide and dexamethasone has provided proof that the medication can extend the time a patient can live without the worsening of his or her disease.